Galderma announces new atopic dermatitis research agreement

Consumer Healthcare News

Galderma has entered into a new research agreement alongside the Icahn School of Medicine at Mount Sinai in New York City, and Northwestern University Feinberg School of Medicine in Chicago.

Focused on the development of new treatment options for patients diagnosed with atopic dermatitis, the arrangement will span the next seven years.

“Galderma has entered into a new research arrangement for the development of new treatment options for atopic dermatitis.“

Atopic dermatitis  is a common chronic inflammatory skin disease that is frequently associated with other allergic diseases such as asthma, hay fever and food allergies.

Amy Paller, Walter J Hamlin professor and chair of dermatology at Northwestern University Feinberg School of Medicine and a physician at the Ann and Robert H Lurie Children’s Hospital of Chicago, stated: "We have recently learned much about the cause of atopic dermatitis, which is driving new therapies. But all of this understanding is based on studies of adults.

"We are looking forward to further dissecting the skin immune system as children age."

The research aims to develop a new understanding of age-specific skin alterations in the development of atopic dermatitis.

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Consumer
Return to news